![Jeffery S. Loutit](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffery S. Loutit
Keine laufenden Positionen mehr
Karriereverlauf von Jeffery S. Loutit
Ehemalige bekannte Positionen von Jeffery S. Loutit
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Rempex Pharmaceuticals, Inc.
![]() Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2011 | 01.12.2013 |
Gründer | 01.11.2011 | 01.12.2013 | |
INTERMUNE INC | Corporate Officer/Principal | - | - |
Stanford University | Corporate Officer/Principal | - | - |
MPEX Pharmaceuticals, Inc.
![]() MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Jeffery S. Loutit
University of Otago | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Neuseeland | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
MPEX Pharmaceuticals, Inc.
![]() MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
InterMune, Inc.
![]() InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Rempex Pharmaceuticals, Inc.
![]() Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Jeffery S. Loutit
- Erfahrung